Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma



Summary

Autologous CD19 CAR-T cell therapy shows promise for treating relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). Studies demonstrate significant efficacy, with high rates of complete remission in heavily pre-treated patients. However, common toxicities include cytokine release syndrome (CRS) and neurotoxicity (immune effector cell-associated neurotoxicity syndrome – ICANS), requiring careful monitoring and management. While these side effects can be serious, they are often manageable with timely interventions. Further research focuses on optimizing CAR-T cell design and delivery to improve efficacy and reduce toxicity for wider application in r/r B-NHL.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!